Dr. Reddy’s Laboratories has just unveiled a groundbreaking solution for migraine sufferers – Nerivio, a wearable device approved by the US Food and Drug Administration (USFDA). This cutting-edge device promises drug-free management of migraines, providing hope and relief for millions of individuals struggling with this debilitating condition.
Picture this: a sleek wearable that fits comfortably on your upper arm, discreet yet powerful. Dr. Reddy’s Laboratories has crafted Nerivio with precision, offering a total of 18 treatment sessions lasting 45 minutes each. But what sets Nerivio apart? It’s not just another gadget; it’s a prescription-based, non-invasive device designed for both the acute and preventive treatment of migraines in adults and adolescents aged 12 years and above.
So, how does it work? When a migraine strikes, timing is crucial. Nerivio is meant to be worn within 60 minutes of the onset of a headache for acute treatment. Alternatively, for preventive measures, it can be used every other day. This flexibility empowers users to manage their migraines on their terms, tailoring the treatment to fit their unique needs.
The impact of migraines is not to be underestimated, especially for the approximately 213 million sufferers in India, where women make up around 60% of this demographic. Recognising the disproportionate impact on women’s lives, Nerivio steps in as a beacon of hope, offering an innovative approach to migraine management.
ALSO READ: Revolutionising Mobility: Beep Launches AutonomOS™ for Seamless Integration of Autonomous Services
In a recent announcement, M.V. Ramana, Chief Executive Officer of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, expressed excitement about Nerivio’s launch, stating, “The roll-out of Nerivio marks our entry into digital therapeutics (DTx).” This move reflects a growing trend among physicians and patients, acknowledging the potential of digital therapeutics to reduce the reliance on conventional medications and alleviate the burden associated with chronic or challenging-to-treat diseases.
Nerivio not only represents a significant leap forward in migraine management but also aligns with Dr. Reddy’s broader business strategies. Ramana highlighted the importance of this new venture, saying, “While our core generics business continues to drive our current growth, Nerivio as DTx joins our e-commerce venture ‘Celevida Wellness.'”
In essence, Nerivio is not just a device; it’s a game-changer in the realm of migraine management. With its sleek design, innovative approach, and the stamp of approval from the USFDA, it signals a new era for individuals seeking relief from migraines. Dr. Reddy’s Laboratories has not only introduced a groundbreaking product but has opened the door to a digital therapeutic landscape that holds promise for those navigating chronic health challenges. So, say goodbye to the pill burden and hello to a new era of migraine management with Nerivio.